Objective To report efficacy and safety of galcanezumab in adults with chronic cluster
headache. Background Galcanezumab is a humanized monoclonal antibody that binds to …

Background Episodic cluster headache is a disabling neurologic disorder that is
characterized by daily headache attacks that occur over periods of weeks or months …

Cluster headache is characterised by attacks of excruciating unilateral headache or facial
pain lasting 15 min to 3 h and is seen as one of the most intense forms of pain. Cluster …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to the
calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical …

Introduction Galcanezumab is a humanized monoclonal antibody binding calcitonin gene-
related peptide, used for migraine prevention. Methods A global, double-blind, 6-month …

Background Galcanezumab, a humanized monoclonal antibody that selectively binds to
calcitonin gene-related peptide, has demonstrated a significant reduction in monthly …

Importance Migraine is a disabling neurological disease characterized by severe headache
attacks. Treatment options reduce migraine frequency for many patients, but adverse effects …

Calcitonin‐gene‐related peptide (CGRP), a neuropeptide broadly distributed in neuronal
and non‐neuronal regions throughout the body, plays a fundamental role in migraine and …

Objective To evaluate onset of effect of galcanezumab in patients with episodic migraine.
Background Galcanezumab is a monoclonal antibody that binds to calcitonin gene‐related …

Background Maintenance of effect following treatment with galcanezumab compared to
placebo in adult patients with episodic or chronic migraine was evaluated. Methods In 2 …